Rahul Majumdar

Betadine® antiseptic products have not been demonstrated to be effective against infections caused by SARS-CoV-2 or any other viruses in vivo, nor have any clinical studies been conducted to assess its safety or effectiveness as a virucidal agent.

 Betadine Topical Antiseptic products currently available in the U.S. are for external use only and should not be gargled or swallowed. Use only as directed on the label. Betadine Sore Throat Gargle (0.5% povidone-iodine antiseptic gargle), which should not be ingested, is used for the temporary relief of sore throat.

 STAMFORD, Conn. – Oct. 14, 2021 – Avrio Health L.P. today announced the publication of results from two in vitro laboratory studies assessing Betadine®antiseptic products (active ingredient: povidone-iodine or “PVP-I”) against four coronaviruses used as a surrogate for SARS-CoV-2. The studies, published in Infectious Diseases and Therapy, found that Betadine Topical Solution, Betadine Surgical Scrub, and Betadine Gargle demonstrated virucidal activity against the coronaviruses studied.

“While further data are needed, publication of these studies helps advance the knowledge of PVP-I’s potential virucidal properties,” said Julie Ducharme, BPharm, MSc, PhD, vice president and chief scientific officer. “Avrio Health is committed to scientific exploration to help inform health care provider response to public health needs.”

This in vitro research evaluated Betadine Topical Solution, Betadine Surgical Scrub, and Betadine Gargle against four coronaviruses used as surrogates to the SARS-CoV-2 virus: Murine Hepatitis Virus Strain A59, a betacoronavirus within the subfamily Coronavirinae-2; as well as human coronavirus strains OC43 (alphacoronavirus), NL63 (alphacoronavirus) and 229E (betacoronavirus) in a second study. These two studies were conducted under ASTM E-1052-11 methods for measuring virucidal time kill to assess the activity of microbicides against viruses.

Betadine Topical Solution (containing 5.0% and 10.0% PVP-I), Betadine Surgical Scrub (containing 7.5% PVP-I), and Betadine Gargle (containing 0.5% PVP-I) were compared to placebo in two separate in vitro studies and showed virucidal activity against four coronaviruses. Betadine Topical Solutions and Gargle showed a 99.99 percent (≥ 4 log) reduction of viral load against one or more strains starting at 15 seconds and at all subsequent time points (30 seconds, 60 seconds and 5 minutes). Results for Betadine Surgical Scrub showed a 99.9 percent (≥ 3 log) reduction across all strains in both studies starting at 15 seconds and at all other time points.¹

“These two studies are part of a research project assessing the safety and effectiveness of Betadine antiseptic products against coronaviruses. While the in vitro nature of the study design prevents clinical interpretation of the findings and further investigations are needed to evaluate SARS-CoV-2 inactivation, this work builds on the current body of knowledge intended to advance the science,” said Craig Landau, MD, president and CEO, Purdue Pharma.

These two studies were funded by Imbrium Therapeutics L.P., in collaboration with Avrio Health.

About Betadine®

Betadine® Topical Antiseptic products have been used in the hospital and outpatient setting for their antimicrobial properties for more than 50 years. Betadine® Topical Antiseptic products currently available in the U.S. are for external use only and should not be gargled or swallowed. Use only as directed on the label. Betadine® Sore Throat Gargle (0.5% povidone-iodine antiseptic gargle), which should not be ingested, is used for the temporary relief of sore throat.

About Avrio Health L.P.

Avrio Health L.P. is a consumer health products company that champions an improved quality of life for people in the United States through the reimagining of innovative product solutions. We have a strong portfolio of well-respected and proven effective brands, including Betadine®, Colace®, Senokot®, and SlowMag® Mg.

Media Contact:
Michele Sharp
(203) 588-7584

1. Shet, M., Hong, R., Igo, D. et al. In Vitro Evaluation of the Virucidal Activity of Different Povidone–Iodine Formulations Against Murine and Human Coronaviruses. Infect Dis Ther (2021). https://doi.org/10.1007/s40121-021-00536-1

STAMFORD, Conn. – Jun 17, 2021 – Avrio Health L.P., a subsidiary of Purdue Pharma L.P., today announced the launch of SlowMag® Mg Calm+Sleep, a dietary supplement with Magnesium Citrate and Melatonin. It supports relaxation, healthy sleep and waking up relaxed.*

SlowMag Mg Calm+Sleep comprises a unique combination of Magnesium and Melatonin that helps your body relax naturally as you drift off to healthy sleep, and promotes a sense of calm and relaxation.* It is formulated with an ideal level of melatonin so you wake up refreshed.* SlowMag Mg tablets are slow to digest. They feature a special enteric coating technology that is designed to reduce the chance of stomach upset. The launch of SlowMag Mg Calm+Sleep is an example of how Avrio Health continues to strengthen its core brand, SlowMag Mg.

This product will be available online and in retail stores this month.

*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

###

About Avrio Health L.P.
Avrio Health L.P., a subsidiary of Purdue Pharma L.P., is a consumer health products company that champions an improved quality of life for people in the United States through the reimagining of innovative product solutions. We have a strong portfolio of well-respected and proven effective brands, including Betadine^®, Colace^®, Senokot^®, and SlowMag® Mg.

About Purdue Pharma L.P.
Purdue Pharma and its subsidiaries develop, manufacture and market medications and consumer health products to meet the evolving needs of healthcare professionals, patients, consumers and caregivers.

The company seeks to achieve a global bankruptcy settlement that would deliver more than $10 billion in value, including 100% of Purdue’s assets and millions of doses of opioid addiction treatment and overdose reversal medicines, to communities across the country to fund programs specifically for abatement of the opioid crisis.  The bankruptcy settlement will also deliver funds to private abatement trusts for the benefit of personal injury claimants.

If Purdue’s settlement is approved, Purdue’s assets will be transferred to a new company.  This new company will be governed by new independent board members, and will operate in a responsible and sustainable manner taking into account long-term public health interests relating to the opioid crisis. The company will continue serving patients and consumers who rely on its medicines and products, pursuing its pipeline, and introducing medicines that will help save and improve lives.

Media Contact:
Michele Sharp
michele.sharp@pharma.com
(203) 585-3195

STAMFORD, Conn. – March 25, 2021 – Avrio Health L.P., a subsidiary of Purdue Pharma L.P., today announced the launch of two Senokot® Dietary Supplement Products: Senokot Laxative* Gummies – Blueberry Pomegranate flavor, and Senokot Laxative* Tea.

Senokot Dietary Supplement Laxative* Gummies – Blueberry Pomegranate flavor is a new flavor of Senokot Laxative* Gummies for gentle overnight relief of occasional constipation. ^†* Made from a natural senna plant, Senokot Laxative* Gummies are for occasional constipation relief.* This product is available online now, and in retail stores in June.

Senokot Dietary Supplement Laxative* Tea is a blend of natural and organic senna and chamomile that offers a sweet flavor with subtle cinnamon and floral notes. Relax with a cup before bedtime to provide overnight relief of occasional constipation. ^†* This product is available online in April and in retail stores in June.

These two products exemplify the ways in which Avrio Health continues to strengthen its core brand, Senokot.

^†When taken at bedtime
*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Additional Information

If pregnant, nursing or taking any medications, consult a healthcare professional before use. Do not take this product if you are allergic to any of the ingredients. Keep out of reach of children. In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.

Do not exceed the recommended amount or use this supplement for longer than 1 week unless directed by a doctor. Read the full product label before using.

###

About Avrio Health L.P.
Avrio Health L.P., a subsidiary of Purdue Pharma L.P., is a consumer health products company that champions an improved quality of life for people in the United States through the reimagining of innovative product solutions. We have a strong portfolio of well-respected and proven effective brands, including Betadine^®, Colace^®, Senokot^®, and SlowMag® Mg.

About Purdue Pharma L.P.
Purdue Pharma and its subsidiaries are physician-founded and physician-led companies that develop, manufacture and market medications and consumer health products to meet the evolving needs of healthcare professionals, patients, consumers and caregivers. Purdue Pharma is also committed to driving innovations in patient care while continuing our efforts to address the opioid crisis.

Purdue’s subsidiaries include: Adlon Therapeutics L.P., focused on treatment options for Attention-Deficit/Hyperactivity Disorder (ADHD) and related disorders; Avrio Health L.P., a consumer wellness company that provides over-the-counter products to fight infection, promote digestive wellness and provide health supplements; Imbrium Therapeutics L.P., established to develop and commercialize non-opioid pain medications and therapies for select oncology and CNS disorders; Rhodes Pharmaceuticals L.P., which develops and supplies primarily solid oral-dose and transdermal medications; and Greenfield Bioventures L.P., an investment vehicle focused on compounds in the early stages of clinical development.

For more information, visit www.purduepharma.com.

Media Contact:
Michele Sharp
michele.sharp@pharma.com
(203) 585-3195

STAMFORD, Conn. – February 08, 2021 – Avrio Health L.P. (Avrio), a subsidiary of Purdue Pharma L.P. (Purdue), today announced the launch of new Betadine^® Antiseptic Oral Rinse (active ingredient 0.5% povidone-iodine, or PVP-I), an oral antiseptic pre-procedural rinse. The product is for professional use only, and is not for retail sale. The Oral Rinse is available through your local dental distributor.

Betadine antiseptic products have been used in the hospital and outpatient settings for their antiseptic (antimicrobial) properties for more than 50 years.

Betadine^® Antiseptic Oral Rinse should be administered by professionals and used orally (do not swallow) in preparation of the oral mucosa prior to injection, dental surgery, or tooth extraction. Do not use this product for more than 7 days unless directed by a dentist or doctor. Do not use this product in children under 12 years of age unless directed by a dentist or doctor. Do not use this product if you are allergic to povidone-iodine or any other ingredients in this product, or if you have any thyroid conditions. For more information, visit www.Betadine.com.

###

About Betadine
Betadine Topical Antiseptic products have been used in the hospital and outpatient setting for their antimicrobial properties for more than 50 years. Betadine Topical Antiseptic products currently available in the U.S. are for external use only and should not be gargled or swallowed. Use only as directed on the label. Betadine Sore Throat Gargle (0.5% povidone-iodine antiseptic gargle), which should not be ingested, is used for the temporary relief of sore throat.

About Avrio Health L.P.
Avrio Health L.P., a subsidiary of Purdue Pharma L.P., is a consumer health products company that champions an improved quality of life for people in the United States through the reimagining of innovative product solutions. We have a strong portfolio of well-respected and proven effective brands, including Betadine^®, Colace^®, Senokot^®, and SlowMag™ Mg.

About Purdue Pharma L.P.
Purdue Pharma and its subsidiaries are physician-founded and physician-led companies that develop, manufacture and market medications and consumer health products to meet the evolving needs of healthcare professionals, patients, consumers and caregivers. Purdue Pharma is also committed to driving innovations in patient care while continuing our efforts to address the opioid crisis.

Purdue’s subsidiaries include: Adlon Therapeutics L.P., focused on treatment options for Attention-Deficit/Hyperactivity Disorder (ADHD) and related disorders; Avrio Health L.P., a consumer wellness company that provides over-the-counter products to fight infection, promote digestive wellness and provide health supplements; Imbrium Therapeutics L.P., established to develop and commercialize non-opioid pain medications and therapies for select oncology and CNS disorders; Rhodes Pharmaceuticals L.P., which develops and supplies primarily solid oral-dose and transdermal medications; and Greenfield Bioventures L.P., an investment vehicle focused on compounds in the early stages of clinical development.

For more information, visit www.purduepharma.com.

Media Contact:
Michele Sharp
michele.sharp@pharma.com
(203) 585-3195

STAMFORD, Conn. – August 13, 2020 – Avrio Health L.P., a subsidiary of Purdue Pharma L.P. (“Purdue”), is reporting encouraging preliminary results of an in vitro (laboratory) study assessing Betadine® Antiseptic Sore Throat Gargle (active ingredient, povidone-iodine or “PVP-I”) against the virus causing COVID-19. Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.

Betadine Gargle containing 0.5% PVP-I demonstrated virucidal activity against SARS-CoV-2 and four surrogate coronaviruses in three separate in vitro studies. An in vitro study conducted by Utah State University, Institute for Antiviral Research, assessed virucidal activity of Betadine Gargle against SARS-CoV-2. In this study, results showed a 99.9 percent reduction of SARS-CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes).

Betadine Gargle was also studied against surrogate coronaviruses: Murine Hepatitis Virus Strain A59, a betacoronavirus within the subfamily Coronavirus, in a second study conducted by BluTest Laboratories, as well as human coronaviruses strains OC43 (alphacoronavirus), NL63 (alphacoronavirus), and 229E (betacoronavirus) in a third study conducted by Bioscience Laboratories. These two studies were conducted under ASTM E-1052- methods for measuring virucidal time kill to assess the activity of microbicides against viruses. In these two studies, results showed a 99.9 percent reduction in viral load starting at 15 seconds and at all subsequent time points (30 seconds, 60 seconds and 5 minutes).

“We are encouraged by these data as we continue to study PVP-I’s potential virucidal properties against the SARS-CoV-2 virus,” said Craig Landau, MD, president and CEO, Purdue Pharma. “Purdue and Avrio Health are committed to leveraging science to address public health needs, and to provide support during this uncharted public health emergency.”

Next, In vivo (human) studies will assess the safety and effectiveness of Betadine Gargle against SARS-CoV-2. Additionally, tests are being conducted on other Betadine formulations, as part of a comprehensive research program assessing the safety and effectiveness of Betadine Antiseptic products (Topical and Gargle) against COVID-19 that began in May.

Other studies on distinct international formulation:
Separately, in vitro studies conducted by the Tropical Infectious Diseases Research and Education Center at the University of Malaya, Malaysia, and at the Duke-NUS Medical School in Singapore, on a separate and distinct formulation of Betadine Gargle available abroad – but not in the U.S. –  found that formulation of Betadine® Gargle (tested at 0.5% and 1.0% PVP-I) killed 99.99% of SARS-CoV-2 at the first timepoints measured.^1,2

###

About Betadine
Betadine Topical Antiseptic products have been used in the hospital and outpatient setting for their antimicrobial properties for more than 50 years. Betadine Topical Antiseptic products currently available in the U.S. are for external use only and should not be gargled or swallowed.  Betadine Antiseptic Sore Throat Gargle (0.5% povidone-iodine antiseptic gargle), which should not be swallowed, is an oral antiseptic with use for the temporary relief of occasional sore throat. Betadine Antiseptic Sore Throat Gargle will be available in retail stores in late August 2020. All products should be used only as directed on the label.

About Avrio Health L.P.
Avrio Health L.P., a subsidiary of Purdue Pharma L.P., is a consumer health products company that champions an improved quality of life for people in the United States through the reimagining of innovative product solutions. We have a strong portfolio of well-respected and proven effective brands, including Betadine®, Colace®, Senokot®, and SlowMag™ Mg.

About Purdue Pharma L.P.
Purdue Pharma and its subsidiaries develop and provide prescription medicines and consumer products that meet the evolving needs of healthcare professionals, patients, consumers and caregivers. We were founded by physicians and are currently led by a physician. Beyond our efforts to provide quality medications, Purdue Pharma is committed to supporting national, regional and local collaborations to drive innovations in patient care while also continuing our efforts to address the opioid crisis.

Purdue’s subsidiaries include: Adlon Therapeutics L.P., focused on treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) and related disorders; Avrio Health L.P., a consumer health products company that champions an improved quality of life for people in the United States through the reimagining of innovative product solutions; Imbrium Therapeutics L.P., established to further advance the emerging portfolio and develop the pipeline in the areas of CNS, non-opioid pain medicines, and select oncology through internal research, strategic collaborations and partnerships; and Greenfield Bioventures L.P., an investment vehicle focused on value-inflection in early stages of clinical development.

For more information, visit www.purduepharma.com.

Media Contact:
Michele Sharp

¹ Anderson, D.E., Sivalingam, V., Kang, A.E.Z. et al. Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease. Infect Dis Ther (2020). https://doi.org/10.1007/s40121-020-00316-3
² Hassandarvish, P., Tiong, V., Sazaly, A. et al. Povidone iodine gargle and mouthwash . Br Dent J 228, 900 (2020). https://doi.org/10.1038/s41415-020-1794-1

STAMFORD, Conn. – August 11, 2020 – Avrio Health L.P. (Avrio), a subsidiary of Purdue Pharma L.P. (Purdue), today announced the launch of new Betadine^® Antiseptic Sore Throat Gargle (active ingredient povidone-iodine, or PVP-I), an oral antiseptic with use for the temporary relief of occasional sore throat.

This new gargle, which will be available in retail stores in late August, joins the Betadine family of topical antiseptic products that help to protect against germs and prevent infection in minor cuts, scrapes and burns. Betadine antiseptic products have been used in the hospital and outpatient setting for their antiseptic (antimicrobial) properties for more than 50 years.

Betadine Antiseptic Sore Throat Gargle should be used orally (do not swallow) for the temporary relief of occasional sore throat. It may be used at the first sign of a sore throat. The product can be used up to four times daily as directed on the label.

Betadine Antiseptic Sore Throat Gargle can be used by adults and children 12 years of age and older. Severe or persistent sore throat or sore throat accompanied by high fever, headache, nausea, and vomiting may be serious. Consult a doctor promptly. Do not use more than 2 days or administer to children under 3 years of age unless directed by a doctor. Do not use this product if you are allergic to povidone-iodine or any other ingredients in this product, or if you have any thyroid conditions. For more information, visit www.Betadine.com.

###

About Betadine

Betadine Topical Antiseptic products have been used in the hospital and outpatient setting for their antimicrobial properties for more than 50 years. Betadine Topical Antiseptic products currently available in the U.S. are for external use only and should not be gargled or swallowed. Use only as directed on the label. Betadine Sore Throat Gargle (0.5% povidone-iodine antiseptic gargle), which should not be ingested, relieves sore throat.

About Avrio Health L.P.

Avrio Health L.P., a subsidiary of Purdue Pharma L.P., is a consumer health products company that champions an improved quality of life for people in the United States through the reimagining of innovative product solutions. We have a strong portfolio of well-respected and proven effective brands, including Betadine^®, Colace^®, Senokot^®, and SlowMag™ Mg.

About Purdue Pharma L.P.

Purdue Pharma and its subsidiaries develop and provide prescription medicines and consumer products that meet the evolving needs of healthcare professionals, patients, consumers and caregivers. We were founded by physicians and are currently led by a physician. Beyond our efforts to provide quality medications, Purdue Pharma is committed to supporting national, regional and local collaborations to drive innovations in patient care while also continuing our efforts to address the opioid crisis.

Purdue’s subsidiaries include: Adlon Therapeutics L.P., focused on treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) and related disorders; Avrio Health L.P., a consumer health products company that champions an improved quality of life for people in the United States through the reimagining of innovative product solutions; Imbrium Therapeutics L.P., established to further advance the emerging portfolio and develop the pipeline in the areas of CNS, non-opioid pain medicines, and select oncology through internal research, strategic collaborations and partnerships; and Greenfield Bioventures L.P., an investment vehicle focused on value-inflection in early stages of clinical development.

For more information, visit www.purduepharma.com.

Media Contact:

Michele Sharp

michele.sharp@pharma.com

(203) 585-3195